GRANT NO:  DAMD17-94-J-4276

TITLE: "Lymphedema:" Incidence, Time Course and Etiology in Long-term Survivors of Breast Cancer Cohort

PRINCIPAL INVESTIGATOR(S): Jeanne A. Petrek, M.D.

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research
New York, New York  10021

REPORT DATE:  September 1995

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland  21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
**Title and Subtitle:** "Lymphedema: Incidence, Time Course and Etiology in Long-term Survivors of Breast Cancer Cohort"

**Authors:** Jeanne A. Petrek, M.D.

**Performing Organization:** Sloan-Kettering Institute for Cancer Research
New York, New York 10021

**Sponsoring/Monitoring Agency:**
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

**Abstract:**
We are employing an existing extensive data base on a cohort of patients treated consecutively between October 1976 and June 1978 who were known to be free of recurrent breast cancer 10 years after diagnosis. The existing data base includes prospectively acquired information (regarding clinical characteristics, intraoperative factors, pathological factors) and the annually-updated medical and cancer history. The medical records have been reviewed for specific anatomical and surgical technique factors that were not part of the original data base but may be associated with lymphedema development. We are interviewing each survivor for a wide range of factors occurring since her cancer treatment, concerning upper extremity activity, function, injury, infection, as well as general activity and health status. We are collecting subjective measurements of lymphedema as well as objective self-reported measurements of arm circumferences. With this study design, we will calculate incidence and rate of lymphedema development. In a nested case-control analysis the women with lymphedema will be matched with women of the same age and stage without lymphedema in order to identify differences that may be predictive of lymphedema development.

**Subject Terms:**
- breast cancer
- lymphedema, arm swelling

**Security Classification:**
- Unclassified

**Distribution Availability Statement:** Approved for public release; distribution unlimited.
# GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to stay within the lines to meet optical scanning requirements.

| Block 1. Agency Use Only (Leave blank). |
| Block 2. Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year. |
| Block 3. Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88). |
| Block 4. Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses. |
| Block 5. Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels: |
| C - Contract | PR - Project |
| G - Grant | TA - Task |
| PE - Program | WU - Work Unit |
| Element | Accession No. |
| Block 6. Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s). |
| Block 7. Performing Organization Name(s) and Address(es). Self-explanatory. |
| Block 8. Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report. |
| Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory. |
| Block 10. Sponsoring/Monitoring Agency Report Number. (If known) |
| Block 11. Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in...; When a report is revised, include a statement whether the new report supersedes or supplements the older report. |
| Block 12a. Distribution/Availability Statement. Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORM, REL, ITAR). |
| DOD - See DoD 5230.24, "Distribution Statements on Technical Documents."
| DOE - See authorities. |
| NTIS - Leave blank. |
| Block 12b. Distribution Code. |
| DOD - Leave blank. |
| DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports. |
| NASA - Leave blank. |
| NTIS - Leave blank. |
| Block 13. Abstract. Include a brief (Maximum 200 words) factual summary of the most significant information contained in the report. |
| Block 14. Subject Terms. Keywords or phrases identifying major subjects in the report. |
| Block 15. Number of Pages. Enter the total number of pages. |
| Block 16. Price Code. Enter appropriate price code (NTIS only). |
| Block 20. Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited. |
FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC–NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRONT COVER</td>
<td>1</td>
</tr>
<tr>
<td>SF 298 REPORT DOCUMENTATION</td>
<td>2</td>
</tr>
<tr>
<td>FOREWORD</td>
<td>3</td>
</tr>
<tr>
<td>TABLE OF CONTENTS</td>
<td>4</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>5</td>
</tr>
<tr>
<td>BODY</td>
<td>7</td>
</tr>
<tr>
<td>CONCLUSIONS</td>
<td>9</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>10</td>
</tr>
<tr>
<td>APPENDIX</td>
<td>11</td>
</tr>
</tbody>
</table>
Introduction

Nature of the Problem: Of all the permanent complications of breast cancer treatment, lymphedema is the most troublesome: The cosmetic deformity can not be disguised with normal clothing, physical discomfort and upper extremity disability is associated with the enlargement and recurrent episodes of cellulitis and lymphangitis may be expected in this setting. Added to the physical symptoms is the distress caused unintentionally by the clinicians, interested in cancer recurrence, who trivialize the non-lethal nature of lymphedema. At least 15% to 20% will develop lymphedema even after modern breast cancer treatment. It is estimated that 1-2 million breast cancer survivors are alive today and at least 200,000 of them cope daily with the disfigurement, discomfort and disability of arm and hand swelling. Despite the human cost, lymphedema has not been systematically studied.

Background of Previous Work: Dr. Jeanne A. Petrek, Principal Investigator, has completed and ongoing protocols involving short and long term complications after breast cancer treatment. (The only major long-term complication is lymphedema.) The research projects concern randomized exercise programs and intraoperative drain techniques. The patients in these research projects are being followed for lymphedema development. They comprise a group of over three hundred relatively recent patients with prospectively gathered clinical, pathologic, and other variables, including preoperative arm measurements by the research nurse. Meaningful data on lymphedema development will require several years. However, these patients are being followed with regular measurements of arm circumferences.

Purpose of the Present Work: We wish to document the incidence, time course, and predictive factors for lymphedema in the survivors of a breast cancer cohort. The current lack of knowledge of factors influencing lymphedema development mandates that all patients be instructed in the same arm and hand care precautions which may be too severe for those at low risk and yet not aggressive enough for those at the highest risk. The aim of the current project is to form a scale of risk for lymphedema depending on variables present at initial treatment and in the subsequent years. Prospective studies would then be performed to validate the scale of risk. As the longterm objective, future patients could receive more individualized anti-lymphedema precautions and a specific followup schedule for early detection of this complication depending upon their risk category.

Methods of Approach: The investigators possess a data base on 1,216 breast cancer patients treated consecutively between 1976 and 1978. It includes epidemiologic information gathered by interview at time of diagnosis, a detailed pathologic analysis, and initial/subsequent cancer and other illness treatment with followup status determined annually. Less than 2% have been lost at followup at 10 years. Study data will include subjective enlargement and arm circumference
measurements, as well as factors previously reported: age, obesity, extent of
dissection, axillary radiation, and arm cellulitis/lymphangitis. The principal
investigator’s ongoing prospective studies have suggested: breast size, previous
arm trauma/surgery, previous breast biopsy, number/proportion of positive lymph
nodes, dominant hand on the treated side, specific surgical techniques and
postoperative fluid formation. Factors in the subsequent years involving arm and
general activity, infection and general health, etc. will be studied: occupations,
sports, and hobbies, weight change, other illnesses, and arm/hand infections,
injuries and surgeries.

Computer files from the existing database and the study data on arm/hand
measurements and interview factors will be linked. Statistical analysis will include
univariate and multivariate tests for the rate and a nested case control analysis for
providing the odds ratio of lymphedema development related to various factors.
Categories will be formed and risk of lymphedema will be rated according to
pertinent variables present at time of diagnosis or in the ensuing years.
Body of Annual Report

Experimental Methods

1. As noted in the Introduction, at time of cancer treatment between 1976 and 1978, a large body of information was gathered and is available on the existing database. Nevertheless, it has required significant labor on the part of Ms. May Nah Ho, the statistician, and Dr. Ruby Senie, the epidemiologist, to rework the database into a form for this study. This included establishing an efficient format for the research nurse, Ms Margaret Peters, to utilize as the new study database enlarges. The prospectively gathered (in 1978-1978) variables are part of the lymphedema database: age, race, height/weight at diagnosis, obesity, menopausal status, previous medical history, medications, size of breast (weight of mastectomy specimen), dominant hand on the treated side, cancer primary size, histologic type/other characteristics, number/proportion of lymph nodes excised with metastatic cancer, perinodal spread.

2. Several variables present at time of operation in 1976 to 1978 were not collected at that time. These include various specific anatomical and surgical factors: excision of thoracodorsal nerve complex, excision of pectoralis minor muscle, length of operation, number of lymph nodes excised, highest level of lymph nodes excised, and specific on postoperative fluid formation, such as total volume of drainage and number of days with the drain. The charts of all study patients were requested, abstracted for these variables, and entered into the database. Since this part of the study data collection began, only 26 charts have not yet been accessed, usually due to their being sent to an outside location for microfilming.

3. The preparation of the telephone interview data collecting questionnaire required several revisions and each revision required further testing with non-protocol patients. The prototype form was utilized with great success in the principal investigator's smaller prospective study with 122 patients who had cancer treatment less than five years ago and who had been accrued preoperatively for the specific study of lymphedema. The interview instrument required the revisions mainly to account for the older age of patients in the present study.

Information obtained from interview consists of weight changes over the interval from diagnosis to the current time, illnesses, operations, medications, hospitalizations (to confirm the pre-existing database information of the annually updated medical history and cancer status), predominant occupation, hobby, sports in the years since diagnosis (for assessment of general and upper extremity activity level), and arm infection/injury or unrelated arm surgery with detailed data
on time of occurrence, length of hospitalization and disability.

4. The preparation of the form for self-reported arm circumferences required significant revisions and testing on non-protocol patients to allow for this specific population with their greater age, decreased dexterity, and sometimes slower comprehension of instructions.

**Addressing tasks in the statement of work**

In the Appendix page || please see the Statement of Work for the project "Lymphedema: Incidence, Time Course, and Etiologic Factors in Long Term Survivors of a Breast Cancer Cohort" that was included in the Army grant application.

Task 1 was achieved with multiple revisions for the appropriate data collecting instruments and returns to pilot testing on non-protocol patients.

Under task 2, the actual interviewing process and collection of self-reported measurements is proceeding. Although there was delay in beginning, with the process now efficient, this phase of the project should conclude on schedule. A full one-third of the study subjects have been contacted. Among these there has been excellent co-operation with the interview process. The self-reported measurements currently in progress have required more research nurse intervention with followup phone calls and reminders than predicted and this process has now been added to the operational system.

Ongoing data entry is proceeding on schedule, as listed in Task 2. c.

Report at Year 1, Task 2. d., is enclosed.
Conclusions

We are employing an existing extensive data base on a cohort of patients treated consecutively between October 1976 and June 1978 who were known to be free of recurrent breast cancer 10 years after diagnosis. The existing data base includes prospectively acquired information (regarding clinical characteristics, intraoperative factors, pathological factors) and the annually-updated medical and cancer history. The medical records have been reviewed for specific anatomical and surgical technique factors that were not part of the original data base but may be associated with lymphedema development. We are interviewing each survivor for a wide range of factors occurring since her cancer treatment, concerning upper extremity activity, function, injury, infection, as well as general activity and health status. We are collecting subjective measurements of lymphedema as well as objective self-reported measurements of arm circumferences with a method tested in non-protocol patients.

With this study design, we will have an accurate incidence and rate of lymphedema development of long-term survivors of a cohort of consecutively treated breast cancer patients. In a nested case-control analysis the women who developed lymphedema will be matched with women of the same age and stage who did not develop lymphedema in order to identify differences that may be predictive of lymphedema development. The odds of developing lymphedema according to the various factors will be calculated. A profile of the patient at low, middle, or high risk for lymphedema development will be constructed.

This analysis is urgent for the potential benefit of future breast cancer patients. Currently each woman is given instructions for arm/hand precautions without taking into account the individual risk factors pertaining to lymphedema development in that woman. However, a more biological approach would be individualization for the prevention precautions and a followup schedule for early detection of this complication based on the patient’s risk. The high risk patient should be admonished in detailed precautions, with reminders at surgeon, radiotherapist, and medical oncologist visits and careful circumference or volumetric measurements at that time. The highest risk patients might fit into a pilot study for aggressive prevention and be fitted with a compression sleeve immediately after surgery. Conversely, patients at low risk would not be advised in the current set of instructions which ban vigorous exercise and even carrying one’s purse on the treated side. The low risk would benefit since they could have greater normalcy in their life. Most patients, however, would probably be in the average risk category and still receive the same instructions in arm/hand precautions.
References none
APPENDIX

STATEMENT OF WORK

Lymphedema: Incidence, Time Course, and Etiologic Factors in Long Term Survivors of A Breast Cancer Cohort

Task 1. Months 1 - 2
   a. Final preparation of data collecting instruments.
   b. Pilot study on non-protocol patients seen for routine followup.

Task 2. Months 3 - 14
   a. Interview of study subjects
   b. Collection of self-reported measurements
   c. Ongoing data entry
   d. Report at Year 1

Task 3: Months 15 - 24
   a. Data analysis
   b. Manuscript/report
INSTRUCTIONS:

1. Please record measurements in inches (red arrow marks indicated on the enclosed tape).

2. Put the hand of the arm being measured on your hip (i.e. right hand on right hip). Please ask someone to assist you with the measuring of your arms.

3. Measure 2 inches above elbow (start at the pointy part of elbows)  
   Measure 6 inches above the elbow points  
   Measure 4 inches below elbow points

   **RIGHT ARM**  **LEFT ARM**

   ————  ————
   ————  ————
   ————  ————